Article Sidebar
Views PDF: 941
EVALUATION OF HBcrAg IN CHRONIC HEPATITIS B PATIENTS TREATED WITH NUCLEOT(s)IDE ANALOGUES (NAs) AT NATIONAL HOSPITAL FOR TROPICAL DISEASES
Main Article Content
Abstract
Objectives: To describe some characteristics of HBcrAg in chronic hepatitis B patients treated with
Nucleot(s)ide Analogues (NAs) with HBV DNA quantitative test results below the detection threshold or undetectable and to determine the correlation coefficient between HBcrAg and other biomarkers. Our study was conducted from November 2022 to August 2023 at the Outpatient Department of Giai Phong campus, National Hospital for Tropical Diseases.
Methods: Cross - sectional descriptive study.
Results and conclusions: 225 patients with chronic hepatitis B with nucleos(t)ide analogues intake for
2 - 4 years were eligible. The median HBcrAg concentration was 4.2 logU/ml. The rate of HBcrAg ≥ 3 was 76.4% that accounted for 3/4 of the study population. HBcrAg concentration had a statistically significant
difference according to HBsAg concentration (p < 0.001) and HBeAg (p < 0.001). HBcrAg concentration
had positive correlated with HBsAg concentration (r = 0.337, p < 0.001) regardless of HBeAg status.
However, HBcrAg concentration was only positively correlated with HBsAg concentration in the HBcrAg
≥ 3 log U/ml group (r = 0.32, p < 0.001) and the HBsAg > 1000 IU/ml group (r = 0.272, p = 0.006). In the group of decreased platelet count , HBcrAg concentration correlated with platelet count in a moderate negative (r = -0.597, p = 0.031).
Article Details
Keywords
HBV, HBV DNA, nucleot(s)ide Analogues (NAs), HBcrAg, HBsAg quatification
References
2. Kimura T, Rokuhara A, Sakamoto Y, Yagi S, Tanaka E, Kiyosawa K, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol. 2002;40(2):439-45.
3. Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, et al. Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. Liver Int. 2017;37(7):995-1001.
4. Li J, Wu Z, Wang GQ, Zhao H. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients. Chin Med J (Engl). 2021;134(10):1160-7.
5. Seto WK, Wong DK, Fung J, Huang FY, Liu KS, Lai CL, et al. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect. 2014;20(11):1173-80.
6. Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3(1):8-19.
7. Brown RS, Jr. Current Management of Thrombocytopenia in Chronic Liver Disease. Gastroenterol Hepatol (N Y). 2019;15(3):155-7.
8. Liao H, Liu Y, Li X, Wang J, Chen X, Zou J, et al. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy. Antivir Ther.
2019;24(2):105-15.
9. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34 Suppl 1:97-107
10. Testoni B, Lebosse F, Scholtes C, Berby F, Miaglia C, Subic M, et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J Hepatol. 201970(4):615-25.